黑皮质素4受体激动剂司美格鲁肽对Bardet-Biedl综合征MASLD及肾功能的影响
结果显示eGFR提升达10.1 mL/min/1.73 m²,BMI z评分、暴食评分、体脂和ATI均改善,85%患者MASLD缓解或稳定在S1级,且MASLD改善仅与肝脏大小相关而与BMI下降无关。
要点
- 司美格鲁肽治疗6个月与BBS患者eGFR提升达10.1 mL/min/1.73 m²相关
- 85%患者MASLD缓解或稳定在S1级,改善独立于BMI下降
- BMI z评分下降0.5,暴食评分下降12.3,体脂下降3.1%
核心结论
- 司美格鲁肽治疗与BBS患者MASLD改善相关,且该改善独立于BMI下降。
- 司美格鲁肽治疗与BBS患者肾小球滤过率升高相关。
研究设计与样本
- 单中心前瞻性观察队列研究,于2023年6月至12月开展。
- 平均年龄19.2岁(范围6.2–51.8),平均BMI z评分2.95(范围1.32–4.84)。
- 采用肝脏超声(含剪切波弹性成像、弥散和衰减成像ATI)、生物电阻抗分析和暴食问卷进行评估。
主要发现
- 治疗6个月后,eGFR提升达10.1 mL/min/1.73 m²(95%CI 4.3–15.9)。
- BMI z评分变化-0.5(95%CI -0.6至-0.3),暴食评分变化-12.3(95%CI -15.5至-9.0)。
- 总休脂变化-3.1%(95%CI -5.7至-0.5),ATI变化-0.14 dB/cm/MHZ(95%CI -0.17至-0.11)。
- 85%患者MASLD缓解或稳定在S1级,MASLD改善仅与肝脏大小相关,与BMI下降无关。
临床怎么用
- 对于基因确诊的BBS伴肥胖和/或暴食患者,可考虑使用司美格鲁肽以改善MASLD和肾功能。
- 司美格鲁肽对MASLD的改善可能不依赖于体重下降,临床评估不应仅以BMI变化判断疗效。
局限性
- 无对照组,无法排除混杂因素对结果的影響。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The melanocortin-4 receptor agonist setmelanotide compensates for upstream gene defects in the brain leptin-melanocortin pathway and reduces hyperphagia and obesity in selected monogenic obesity forms and Bardet-Biedl syndrome (BBS). We aimed to evaluate the short-term impact of setmelanotide treatment in BBS presenting original real-world data focusing on metabolic dysfunction-associated steatotic liver disease (MASLD) and kidney function. METHODS: This monocentric, prospective observational cohort study was performed between June and December 2023 and included patients above the age of 6 years with genetically confirmed BBS, obesity, and/or hyperphagia and planned setmelanotide therapy. Ultrasound examination of the liver including shear wave elastography, dispersion and attenuation imaging (ATI), a bioimpedance analysis, and a hyperphagia questionnaire survey were applied in addition to clinical data collection. RESULTS: Twenty-six patients with BBS (mean age 19.2 years, range [6.2; 51.8]; mean body mass index (BMI) z-score 2.95, range [1.32; 4.84]) were included. All were classified with MASLD (54% S3, 23% each S1 and S2). After 6 months of setmelanotide treatment, estimated glomerular filtration rate increased up to 10.1 mL/min/1.73 m² (95% confidence interval (CI) [4.3; 15.9]). The following parameters also improved: BMI z-score -0.5 (95% CI [-0.6; -0.3]); hyperphagia score -12.3 (95% CI [-15.5; -9.0]); total body fat -3.1% (95% CI [-5.7; -0.5]); ATI -0.14 dB/cm/MHZ (95% CI [-0.17; -0.11]). A total of 85% of patients exhibited either resolution of MASLD or stabilization at grade S1. MASLD improvement correlated only with liver size, not BMI reduction. CONCLUSION: Setmelanotide treatment is associated with improvement of MASLD independent of BMI reduction as well as increased glomerular filtration rate in BBS.
引用
- Hühne T, Polichronidou IM, Finkelberg I, et al. Impact of the Melanocortin-4 Receptor Agonist Setmelanotide on MASLD and Kidney Function in Bardet-Biedl Syndrome. J Clin Endocrinol Metab. 2026. PMID: 40903014. doi:10.1210/clinem/dgaf483
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。